These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Rubinstein MR; Baik JE; Lagana SM; Han RP; Raab WJ; Sahoo D; Dalerba P; Wang TC; Han YW EMBO Rep; 2019 Apr; 20(4):. PubMed ID: 30833345 [No Abstract] [Full Text] [Related]
23. Association Between Fusobacterium nucleatum, Pathway Mutation, and Patient Prognosis in Colorectal Cancer. Lee DW; Han SW; Kang JK; Bae JM; Kim HP; Won JK; Jeong SY; Park KJ; Kang GH; Kim TY Ann Surg Oncol; 2018 Oct; 25(11):3389-3395. PubMed ID: 30062471 [TBL] [Abstract][Full Text] [Related]
24. Fusobacterium nucleatum tumor DNA levels are associated with survival in colorectal cancer patients. Kunzmann AT; Proença MA; Jordao HW; Jiraskova K; Schneiderova M; Levy M; Liska V; Buchler T; Vodickova L; Vymetalkova V; Silva AE; Vodicka P; Hughes DJ Eur J Clin Microbiol Infect Dis; 2019 Oct; 38(10):1891-1899. PubMed ID: 31367996 [TBL] [Abstract][Full Text] [Related]
25. Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer. Nosho K; Sukawa Y; Adachi Y; Ito M; Mitsuhashi K; Kurihara H; Kanno S; Yamamoto I; Ishigami K; Igarashi H; Maruyama R; Imai K; Yamamoto H; Shinomura Y World J Gastroenterol; 2016 Jan; 22(2):557-66. PubMed ID: 26811607 [TBL] [Abstract][Full Text] [Related]
26. Single-cell RNA sequencing analysis reveals the distinct features of colorectal cancer with or without Ding T; Chen Q; Liu H; Zhang H; Sun Y; Zhao L; Gao Y; Wei Q Heliyon; 2024 Sep; 10(18):e37511. PubMed ID: 39309908 [TBL] [Abstract][Full Text] [Related]
27. Fusobacterium nucleatum-derived succinic acid induces tumor resistance to immunotherapy in colorectal cancer. Jiang SS; Xie YL; Xiao XY; Kang ZR; Lin XL; Zhang L; Li CS; Qian Y; Xu PP; Leng XX; Wang LW; Tu SP; Zhong M; Zhao G; Chen JX; Wang Z; Liu Q; Hong J; Chen HY; Chen YX; Fang JY Cell Host Microbe; 2023 May; 31(5):781-797.e9. PubMed ID: 37130518 [TBL] [Abstract][Full Text] [Related]
28. Profiling Fusobacterium infection at high taxonomic resolution reveals lineage-specific correlations in colorectal cancer. Bi D; Zhu Y; Gao Y; Li H; Zhu X; Wei R; Xie R; Cai C; Wei Q; Qin H Nat Commun; 2022 Jun; 13(1):3336. PubMed ID: 35680952 [TBL] [Abstract][Full Text] [Related]
29. Hong J; Guo F; Lu SY; Shen C; Ma D; Zhang X; Xie Y; Yan T; Yu T; Sun T; Qian Y; Zhong M; Chen J; Peng Y; Wang C; Zhou X; Liu J; Liu Q; Ma X; Chen YX; Chen H; Fang JY Gut; 2021 Nov; 70(11):2123-2137. PubMed ID: 33318144 [TBL] [Abstract][Full Text] [Related]
30. Effects of metronidazole on colorectal cancer occurrence and colorectal cancer liver metastases by regulating Fusobacterium nucleatum in mice. Wang M; Li Y; Yang X; Liu Z; Wang K; Gong D; Li J Immun Inflamm Dis; 2023 Nov; 11(11):e1067. PubMed ID: 38018574 [TBL] [Abstract][Full Text] [Related]
31. Metformin elicits antitumour effect by modulation of the gut microbiota and rescues Fusobacterium nucleatum-induced colorectal tumourigenesis. Huang X; Hong X; Wang J; Sun T; Yu T; Yu Y; Fang J; Xiong H EBioMedicine; 2020 Nov; 61():103037. PubMed ID: 33039709 [TBL] [Abstract][Full Text] [Related]
32. TOX expression decreases with progression of colorectal cancers and is associated with CD4 T-cell density and Fusobacterium nucleatum infection. Chen T; Li Q; Zhang X; Long R; Wu Y; Wu J; Fu X Hum Pathol; 2018 Sep; 79():93-101. PubMed ID: 29792893 [TBL] [Abstract][Full Text] [Related]
33. Fusobacterium nucleatum promotes tumor progression in KRAS p.G12D-mutant colorectal cancer by binding to DHX15. Zhu H; Li M; Bi D; Yang H; Gao Y; Song F; Zheng J; Xie R; Zhang Y; Liu H; Yan X; Kong C; Zhu Y; Xu Q; Wei Q; Qin H Nat Commun; 2024 Feb; 15(1):1688. PubMed ID: 38402201 [TBL] [Abstract][Full Text] [Related]
34. Chen Y; Chen Y; Zhang J; Cao P; Su W; Deng Y; Zhan N; Fu X; Huang Y; Dong W Theranostics; 2020; 10(1):323-339. PubMed ID: 31903123 [No Abstract] [Full Text] [Related]
36. Circulating Bacterial DNA in Colorectal Cancer Patients: The Potential Role of Koliarakis I; Lagkouvardos I; Vogiatzoglou K; Tsamandouras I; Intze E; Messaritakis I; Souglakos J; Tsiaoussis J Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201711 [TBL] [Abstract][Full Text] [Related]
37. Iron accelerates Fusobacterium nucleatum-induced CCL8 expression in macrophages and is associated with colorectal cancer progression. Yamane T; Kanamori Y; Sawayama H; Yano H; Nita A; Ohta Y; Hinokuma H; Maeda A; Iwai A; Matsumoto T; Shimoda M; Niimura M; Usuki S; Yasuda-Yoshihara N; Niwa M; Baba Y; Ishimoto T; Komohara Y; Sawa T; Hirayama T; Baba H; Moroishi T JCI Insight; 2022 Nov; 7(21):. PubMed ID: 36136589 [TBL] [Abstract][Full Text] [Related]
38. Association of Fusobacterium nucleatum infection and colorectal cancer: A Mexican study. Cuellar-Gómez H; Ocharán-Hernández ME; Calzada-Mendoza CC; Comoto-Santacruz DA Rev Gastroenterol Mex (Engl Ed); 2022; 87(3):277-284. PubMed ID: 34312118 [TBL] [Abstract][Full Text] [Related]
39. Fusobacterium nucleatum promotes colon cancer progression by changing the mucosal microbiota and colon transcriptome in a mouse model. Wu N; Feng YQ; Lyu N; Wang D; Yu WD; Hu YF World J Gastroenterol; 2022 May; 28(18):1981-1995. PubMed ID: 35664967 [TBL] [Abstract][Full Text] [Related]
40. Both endogenous and exogenous miR-139-5p inhibit Fusobacterium nucleatum-related colorectal cancer development. Zhao Y; Tao Q; Li S; Zheng P; Liu J; Liang X Eur J Pharmacol; 2020 Dec; 888():173459. PubMed ID: 32768506 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]